Physician profile
Ali Hemdan
NPI 1366692691
$5,873.36
in general payments reported to CMS, 2019-2025
30 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $402 · 2021: $621 · 2022: $1,937 · 2023: $716 · 2024: $820 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.47 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,451.37 | 2022-2025 | Monarch Platform |
| Glaxosmithkline, LLC. | $1,403.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $674.12 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.85 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $279.18 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $245.71 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Amgen INC. | $173.44 | 2022-2025 | Tezspire, Uplizna |
| Genzyme Corporation | $173.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Pfizer INC. | $92.00 | 2021-2023 | |
| Philips North America LLC | $89.50 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Grifols USA, LLC | $88.63 | 2021-2024 | Xembify |
| Baxter Healthcare | $78.86 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $75.41 | 2021-2023 | Acthar |
| Mylan Specialty L.P. | $58.18 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.12 | 2019 | |
| Octapharma USA, INC. | $47.64 | 2024-2025 | Cutaquig |
| Electromed, INC. | $47.39 | 2022-2023 | Smartvest |
| Csl Behring | $44.92 | 2019-2024 | Hizentra |
| United Therapeutics Corporation | $44.47 | 2024-2025 | Tyvaso |
| Genentech USA, INC. | $43.16 | 2019-2020 | |
| Circassia INC. | $38.14 | 2019 | |
| Insmed, INC. | $35.63 | 2020-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $34.97 | 2024 | Opsumit |
| Verona Pharma, INC. | $32.21 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $29.03 | 2025 | Yupelri |
| 3b Medical, INC. | $28.83 | 2025 | Luna |
| Abbvie INC. | $27.59 | 2023 | |
| Covis Pharma Gmbh | $25.56 | 2022 | |
| Phadia US INC. | $15.56 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hemdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.